Results 261 to 270 of about 15,238,642 (306)
Some of the next articles are maybe not open access.
Chimeric antigen receptor T-cell therapy for melanoma
Expert Review of Clinical Immunology, 2021In recent years, chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment. After initial therapeutic success for hematologic malignancies, this approach has been extended for the treatment of solid tumors including melanoma.T cells need to be reprogramed to recognize specific antigens expressed only in tumor cells, a difficult ...
Azadehsadat Razavi +3 more
openaire +2 more sources
Chimeric antigen receptor T‐cell therapy toxicities
British Journal of Clinical Pharmacology, 2020Cancer immunotherapy has greatly advanced in recent years, with chimeric antigen receptor (CAR) T cells emerging as an innovative technology that harnesses the immune system to fight malignant diseases. These genetically engineered T‐cells have shown encouraging results for B‐cell lymphoid malignancies and are now being explored for other cancer types.
Uri Greenbaum +7 more
openaire +2 more sources
Chimeric Antigen Receptors for T-Cell Based Therapy
2012The Chimeric Antigen Receptor (CAR) consists of an antibody-derived targeting domain fused with T-cell signaling domains that, when expressed by a T-cell, endows the T-cell with antigen specificity determined by the targeting domain of the CAR. CARs can potentially redirect the effector functions of a T-cell towards any protein and nonprotein target ...
Cheadle, Eleanor +11 more
openaire +5 more sources
Chimeric antigen receptor T-cell therapies for lymphoma
Nature Reviews Clinical Oncology, 2017New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and relapse after autologous stem-cell transplantation are indicators of an especially poor prognosis.
Jennifer N, Brudno +1 more
openaire +2 more sources
The Future of Chimeric Antigen Receptor T Cell Therapy
Hematology/Oncology Clinics of North America, 2023Over the last 10 years CAR T cell therapies have been shown to be transformative for B- and plasma-cell malignancies, however the field is only beginning to realize the potential benefit to patients of such therapies. Over the next 10 years it is expected that advances will be made in durable response rates for patients with B/plasma cell malignancies;
openaire +2 more sources
Chimeric antigen receptor T-cell therapy for glioblastoma
Translational Research, 2017Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in the treatment of hematological disease, and its utility for treatment of solid tumors is beginning to unfold. Glioblastoma continues to portend a grim prognosis and immunotherapeutic approaches are being explored as a potential treatment strategy.
Analiz Rodriguez +2 more
openaire +2 more sources
A review of chimeric antigen receptor T-cells in lymphoma
Expert Review of Hematology, 2019Introduction: Immunotherapy has revolutionized the treatment of cancer. Antibodies, antibody drug conjugates, and bispecific antibodies have improved outcomes in various cancers especially lymphomas. Chimeric antigen receptor T cell (CAR-T) is a step forward in the immunotherapy paradigm for the treatment of Lymphomas.
Jennifer Kelly Anderson, Amitkumar Mehta
openaire +2 more sources
Imaging of T Cells Expressing Chimeric Antigen Receptors
Immunotherapy, 20111411 ISSN 1750-743X Immunotherapy (2011) 3(12), 1411–1414 10.2217/IMT.11.138 © 2011 Future Medicine Ltd “Macroscopic imaging, exemplified by bioluminescent imaging, PET and MRI has been useful for establishing the trafficking pattern of adoptively transferred chimeric antigen receptor (CAR)+ T cells, their persistence and antitumor activity ...
Janos, Roszik +2 more
openaire +2 more sources
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
BioDrugs, 2019Chimeric antigen receptor (CAR) T-cell immunotherapy has gained significant attention in the past decade due to its considerable potential in the treatment of various types of malignancies, particularly hematological. While success has been achieved in a number of studies, and two CAR-T-cell products were recently approved by the US Food and Drug ...
Boris Gorovits, Eugen Koren
openaire +2 more sources
The road ahead for chimeric antigen receptor T cells
The Journal of ImmunologyAbstract Chimeric antigen receptor T (CART) cell therapy is an innovative form of immunotherapy that has shown remarkable and long-term responses in patients with B-cell malignancies. Over the years, the field has made significant progress in our understanding of the successes and challenges associated with CART cell therapy.
Carli M, Stewart +2 more
openaire +2 more sources